|
|
Volumn 33, Issue 10, 2015, Pages 1180-1185
|
|
Randomized phase III trial of gemcitabine plus docetaxel plus bevacizumab or placebo as first-line treatment for metastatic uterine leiomyosarcoma: An NRG oncology/ gynecologic oncology group study
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
BEVACIZUMAB;
DEXAMETHASONE;
DIURETIC AGENT;
DOCETAXEL;
FILGRASTIM;
GEMCITABINE;
PEGFILGRASTIM;
PLACEBO;
ANTINEOPLASTIC AGENT;
DEOXYCYTIDINE;
MONOCLONAL ANTIBODY;
TAXOID;
ADULT;
AGED;
ANEMIA;
ARTICLE;
CANCER COMBINATION CHEMOTHERAPY;
CONTROLLED STUDY;
DOUBLE BLIND PROCEDURE;
FEMALE;
FISTULA;
GASTROINTESTINAL HEMORRHAGE;
HUMAN;
HYPERTENSION;
LYMPHEDEMA;
MAJOR CLINICAL STUDY;
METASTATIC UTERINE LEIOMYOSARCOMA;
NEUTROPENIA;
OVERALL SURVIVAL;
PHASE 3 CLINICAL TRIAL;
PRIORITY JOURNAL;
PROGRESSION FREE SURVIVAL;
RANDOMIZED CONTROLLED TRIAL;
THROMBOCYTOPENIA;
THROMBOEMBOLISM;
TREATMENT OUTCOME;
TREATMENT RESPONSE;
UTERUS SARCOMA;
ANALOGS AND DERIVATIVES;
CHEMICALLY INDUCED;
CLINICAL TRIAL;
DISEASE FREE SURVIVAL;
KAPLAN MEIER METHOD;
LEIOMYOSARCOMA;
METASTASIS;
MIDDLE AGED;
PATHOLOGY;
TIME FACTOR;
UTERINE NEOPLASMS;
ADULT;
AGED;
ANEMIA;
ANTIBODIES, MONOCLONAL, HUMANIZED;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
BEVACIZUMAB;
DEOXYCYTIDINE;
DISEASE-FREE SURVIVAL;
DOUBLE-BLIND METHOD;
FEMALE;
HUMANS;
KAPLAN-MEIER ESTIMATE;
LEIOMYOSARCOMA;
MIDDLE AGED;
NEOPLASM METASTASIS;
TAXOIDS;
THROMBOCYTOPENIA;
TIME FACTORS;
TREATMENT OUTCOME;
UTERINE NEOPLASMS;
|
|
EID: 84927644800
PISSN: 0732183X
EISSN: 15277755
Source Type: Journal
DOI: 10.1200/JCO.2014.58.3781 Document Type: Article |
|
Times cited : (104)
|
|
References (11)
|
